Cochrane Library

Cochrane Database of Systematic Reviews

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (Review)

Abdel-Rahman O, Elsayed Z

Abdel-Rahman O, Elsayed Z.
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No.: CD011313.
DOI: 10.1002/14651858.CD011313.pub4.

www.cochranelibrary.com

WILEY

TABLE OF CONTENTS

[Intervention Review]

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma

Omar Abdel-Rahman[1], Zeinab Elsayed[2]

[1]Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Canada. [2]Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Contact: Omar Abdel-Rahman, omar.abdelrhman@med.asu.edu.eg.

Editorial group: Cochrane Hepato-Biliary Group.
Publication status and date: Withdrawn from publication for reasons stated in the review, published in Issue 10, 2021.

Citation: Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. *Cochrane Database of Systematic Reviews* 2020, Issue 11. Art. No.: CD011313. DOI: 10.1002/14651858.CD011313.pub4.

REASON FOR WITHDRAWAL FROM PUBLICATION

This review was withdrawn on 16 November 2020. The withdrawal notice originally cited a comment received and other methodological problems as the reason for withdrawal. An additional statement by the Editor in Chief of the Cochrane Library has been added (12 October 2021).

Statement by the Editor in Chief:

In February 2021, an article was posted by Retraction Watch describing the submission of a comment and the subsequent process leading to the withdrawal of this review: retractionwatch.com/2021/02/11/leading-evidence-based-group-blames-pandemic-for-9-month-delay-pulling-flawed-cancer-review. The statement attributed to the Cochrane Hepato-Biliary Group cited the methodological quality of the published review and the COVID 19 pandemic as reasons for delay in the withdrawal of the review. Having examined the process of the correction and the editorial process, the Editor in Chief is satisfied that the principal reason for the delay in withdrawal of the review relates to a disagreement between the two parties over the methods and data in the review. There were no concerns regarding the integrity of the author team and the authors will be invited to resubmit the corrected review for editorial consideration with a view to reinstatement in the *Cochrane Database of Systematic Reviews*.

Previous withdrawal statements relating this review:

16 November 2020: Due to a comment received and due to some other identified methodological problems, the present review is withdrawn.

22 June 2021: This review has been withdrawn due to the way in which mortality has been framed, analysed, and reported in the review. The approach to the analysis of the primary outcome of survival has not been consistently applied, leading to potential confusion for the reader.

The editorial group responsible for this previously published document have withdrawn it from publication.

WHAT'S NEW

Date	Event	Description
12 October 2021	Amended	Reasons for withdrawal updated

HISTORY

Protocol first published: Issue 9, 2014
Review first published: Issue 2, 2016

Date	Event	Description
22 June 2021	Amended	The CHBG plans to publish an updated version of the review when ready.
16 November 2020	New search has been performed	We updated searches and search results. We identified 4 new trials for inclusion in the review
16 November 2020	New citation required and conclusions have changed	In the previously published review version, we concluded that evidence was insufficient to assess the beneficial and harmful effects of yttrium-90 microsphere radioembolisation compared with no treatment, sham radioembolisation, or other systemic or locoregional therapies for people with hepatocellular carcinoma In this updated review version, we added to the previous conclusion that "...Radioembolisation compared with sorafenib seemed to achieve equivalent survival and to cause less adverse effects, but our certainty is low to very low", and in general, better formulated our conclusions

SOURCES OF SUPPORT

Internal sources

- None, Other

External sources

- None, Other